Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2004 3
2005 1
2007 1
2008 2
2009 3
2010 1
2011 2
2012 1
2013 1
2014 1
2015 1
2019 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
Bendamustine: rebirth of an old drug.
Cheson BD, Rummel MJ. Cheson BD, et al. Among authors: rummel mj. J Clin Oncol. 2009 Mar 20;27(9):1492-501. doi: 10.1200/JCO.2008.18.7252. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224851 Review.
Altered apoptosis pathways in mantle cell lymphoma.
Rummel MJ, de Vos S, Hoelzer D, Koeffler HP, Hofmann WK. Rummel MJ, et al. Leuk Lymphoma. 2004 Jan;45(1):49-54. doi: 10.1080/1042819031000151112. Leuk Lymphoma. 2004. PMID: 15061196 Review.
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
Zimmermann H, Koenecke C, Dreyling MH, Pott C, Dührsen U, Hahn D, Meidenbauer N, Hauser IA, Rummel MJ, Wolf D, Heuser M, Schmidt C, Schlattmann P, Ritgen M, Siebert R, Oschlies I, Anagnostopoulos I, Trappe RU. Zimmermann H, et al. Among authors: rummel mj. Leukemia. 2022 Oct;36(10):2468-2478. doi: 10.1038/s41375-022-01667-1. Epub 2022 Aug 16. Leukemia. 2022. PMID: 35974101 Free PMC article. Clinical Trial.
23 results